mirikizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
monoclonal antibodies (humanized origin); interleukin and interleukin receptors 5722 1884201-71-1

Description:

MoleculeDescription

Molfile

Synonyms:

  • mirikizumab
  • omvoh
  • LY3074828
Mirikizumab is a humanised IgG4 monoclonal, anti-interleukin-23 (anti-IL-23) antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23, a regulatory cytokine, affects the differentiation, expansion, and survival of T cell subsets, (e.g., Th17 cells and Tc17 cells) and innate immune cell subsets, which represent sources of effector cytokines, including IL-17A, IL-17F and IL-22 that drive inflammatory disease. In humans, selective blockade of IL-23 was shown to normalise production of these cytokines.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
7.10 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
May 26, 2023 EMA ELI LILLY NEDERLAND B.V.
March 27, 2023 PMDA Eli Lilly Japan K.K.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Haematochezia 70.28 59.78 20 202 115504 110473573

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC24 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
MeSH PA D000700 Analgesics
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D000897 Anti-Ulcer Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018501 Antirheumatic Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D018712 Analgesics, Non-Narcotic
FDA MoA N0000192798 Interleukin-23 Antagonists
FDA EPC N0000192799 Interleukin-23 Antagonist
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

L04AC Interleukin inhibitors 18 drugs
anakinrabasiliximabbimekizumabbrodalumabcanakinumabdaclizumabguselkumabixekizumabrilonaceptrisankizumabsarilumabsatralizumab show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Moderately to severely active ulcerative colitis indication 64766004 DOID:8577
Active tuberculosis contraindication 427099000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-23 subunit alpha Cytokine BINDING AGENT Kd 10.68 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEBI:756496 CHEBI
CHEMBL3990014 ChEMBL_ID
C000708407 MESH_SUPPLEMENTAL_RECORD_UI
9846 IUPHAR_LIGAND_ID
DB14910 DRUGBANK_ID
2054111000122105 SNOMEDCT_US
4042727 VANDF
C5139904 UMLSCUI
10657 INN_ID
372963 MMSL
42125 MMSL
d10126 MMSL
D11123 KEGG_DRUG
Z7HVY03PHP UNII
2668384 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Omvoh HUMAN PRESCRIPTION DRUG LABEL 1 0002-1442 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 30 sections
Omvoh HUMAN PRESCRIPTION DRUG LABEL 1 0002-3116 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 30 sections
Omvoh HUMAN PRESCRIPTION DRUG LABEL 1 0002-3116 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 30 sections
Omvoh HUMAN PRESCRIPTION DRUG LABEL 1 0002-7575 INJECTION, SOLUTION 20 mg INTRAVENOUS BLA 30 sections
Omvoh HUMAN PRESCRIPTION DRUG LABEL 1 0002-7575 INJECTION, SOLUTION 20 mg INTRAVENOUS BLA 30 sections
Omvoh HUMAN PRESCRIPTION DRUG LABEL 1 0002-8011 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 30 sections
Omvoh HUMAN PRESCRIPTION DRUG LABEL 1 0002-8011 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 30 sections
Omvoh HUMAN PRESCRIPTION DRUG LABEL 1 0002-8870 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 30 sections
Omvoh HUMAN PRESCRIPTION DRUG LABEL 1 0002-8870 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 30 sections